Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Gemcitabine 3Nivolumab 2temoporfin 1spartalizumab 1polysaccharide-K 1pembrolizumab 1nimotuzumab 1devimistat 1dalotuzumab 1bemarituzumab 1belinostat 1Transurethral Resection of Prostate 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiofrequency Ablation 1Oxaliplatin 1Morphine 1Methadone 1Leucovorin 1Ipilimumab 1Interviews as Topic 1Injections 1Immunotherapy 1Heavy Ion Radiotherapy 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cryosurgery 1Cisplatin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adenocarcinoma × spartalizumab × Clear all
NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡